SPRY ARS Pharmaceuticals
- 8.890
- +0.150+1.72%
- 9.000
- +0.110+1.24%
ARS Pharmaceuticals News
ARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns With EPS Projections Amidst Regulatory ...
ARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 Loss per Share (Vs US$0.16 Loss in 1Q 2023)
ARS Pharmaceuticals Unveils Updated Corporate Presentation
ARS Pharmaceuticals (SPRY.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $20,000; earnings per share of -0.11 dollars, previous value of -0.16 dollars, expected value of -0.11 dollars.
ARS Pharmaceuticals (SPRY.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $20,000; earnings per share of -0.11 dollars, previous value of -0.16 dollars, expected value of -0.11 dollars.
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$934.37K in Common Stock
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder Lowenthal Richard E sold 100K shares of common stock on May 7, 2024 at an average price of $9.3437 for a total value of $934.37K. This transaction involv
ARS Pharmaceuticals Q1 2024 GAAP EPS $(0.11), Inline
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate.
ARS Pharmaceuticals | 10-Q: Quarterly report
ARS Pharmaceuticals Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement With CSL Seqirus for Commercialization of Neffy in Australia and New Zealand
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose
Insider Trading: ARS Pharmaceuticals' (NASDAQ:SPRY) Insiders Buy Shares Worth $679K
Market Sentiment Around Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. ARS Pharmaceuticals, Inc., a biopharmaceutica
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing
Richard E Lowenthal, 10% Owner, Director, PRESIDENT AND CEO, on April 16, 2024, sold 100,000 shares in ARS Pharmaceuticals (SPRY) for $928,005. Following the Form 4 filing with the SEC, Lowenthal has
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$928.01K in Common Stock
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder Lowenthal Richard E sold 100K shares of common stock on Apr 16, 2024 at an average price of $9.2801 for a total value of $928.01K. This transaction invol
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Sells US$927.73K in Common Stock
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder Lowenthal Richard E sold 100K shares of common stock on Apr 9, 2024 at an average price of $9.2773 for a total value of $927.73K. This transaction involv
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing
Richard E Lowenthal, 10% Owner, Director, President and CEO, on April 09, 2024, sold 100,000 shares in Ars Pharmaceuticals (SPRY) for $927,735. Following the Form 4 filing with the SEC, Lowenthal has
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors -- Barrons.com
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequen
ARS Pharmaceuticals Responded to FDA CRL for Epinephrine Nasal Spray
ARS Pharmaceuticals Submits Response To FDA Complete Response Letter For Neffy
Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detecte
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
Top 5 Health Care Stocks That May Plunge In March
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicat
ARS Pharmaceuticals(SPRY.US) 10% Shareholder Buys US$13.29 Million in Common Stock
$ARS Pharmaceuticals(SPRY.US)$ 10% Shareholder RA CAPITAL MANAGEMENT, L.P. purchased 1.4 million shares of Common Stock on Mar 25, 26, 27, 2024 at an average price of $9.48 for a total value of $13.29
Analysis
Price Target
No Data
